| Autor: |
Gonzalo, Díaz-Soto, Pablo, Fernández-Velasco, Beatriz, Torres Torres, Juan José, López Gómez, Susana, García Calvo, Daniel, de Luis Román |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Endocrinología, Diabetes y Nutrición (English ed.). 69:844-851 |
| ISSN: |
2530-0180 |
| DOI: |
10.1016/j.endien.2022.11.031 |
| Popis: |
To evaluate the adequacy of TSH suppression therapy (TSHst) at the first disease assessment and the last follow-up visit.Retrospective observational study of those patients under follow-up of DTC in a reference hospital.216 patients (79.2% women) were evaluated, with a mean age 59.0 ± 13.1 years-old and a mean follow-up of 6.9 ± 4.3 years. 88.4% were papillary carcinomas. At diagnosis, 69.2% had a low risk of recurrence (RR) compared to 13.6% with a high RR. Dynamic risk stratification (DRS) classified patients at first disease assessment and the last visit as excellent response (ER) in 60.0% and 70.7%, respectively. Those patients with ER in the first and last follow-up control maintained TSHst in 30.7% and 16.3% of the cases, respectively (p 0.001). The factors associated with maintaining TSHst at the last control were younger age, higher RR at diagnosis, DRE at follow-up, presence of multifocality and histological vascular invasion (p 0.05). In a logistic regression analysis adopting tsTSH at follow-up as the dependent variable, exclusively age (β = -0.062; p 0.001), RR at diagnosis (β = 1.074; p 0.05) and EDR during follow-up (β = 1.237; p 0.05) maintained statistical significance.Despite the current recommendations, 30.7% of patients with low RR and initial ER are under TSHst. This percentage reduced to 16.3% in those patients with ER after a mean follow-up of 6.9 years. Age, baseline RR, and DRE during follow-up were associated to maintaining tsTSH. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect